Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody ?) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumors
CANCER RESEARCH（2023）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要